In a rather unusual move, a Wall Street analyst has written an open letter to Gilead Sciences, imploring the drug maker’s executive team to pursue a “meaningful” acquisition before cash flow declines too precipitously.
The missive, which was written by Barclays Bank analyst Geoff Meacham, reflects ongoing investor frustration that the company has yet to pursue a deal to help compensate for declining sales of hepatitis C drugs and disappointing study results for newer medicines.
About the Author Reprints
